
Ask a doctor about a prescription for OLMESARTAN/HYDROCHLOROTHIAZIDE MABO 40 mg/25 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Olmesartan/Hydrochlorothiazide MABO 40 mg/25 mg film-coated tablets EFG
Olmesartan medoxomil/hydrochlorothiazide
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Keep this leaflet, as you may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
What is in this leaflet:
Olmesartan/Hydrochlorothiazide MABO contains two active substances, olmesartan medoxomil and hydrochlorothiazide, which are used to treat high blood pressure (hypertension):
Olmesartan medoxomil works by blocking the action of a natural chemical that narrows blood vessels, allowing blood vessels to widen, which lowers blood pressure.
Hydrochlorothiazide works by increasing the amount of urine produced by the kidneys, which helps to remove excess fluid and salt from the body, reducing blood pressure.
Olmesartan/Hydrochlorothiazide MABO will only be given to you if treatment with olmesartan medoxomil alone has not controlled your blood pressure sufficiently. The combination of the two active substances in Olmesartan/Hydrochlorothiazide MABO has been shown to be more effective at reducing blood pressure than either substance alone.
You may already be taking medicines to treat high blood pressure, but your doctor may think it is necessary for you to take Olmesartan/Hydrochlorothiazide MABO to lower it further.
High blood pressure can be treated with medicines such as Olmesartan/Hydrochlorothiazide MABO tablets. Your doctor may also have recommended that you make some changes to your lifestyle, such as losing weight, stopping smoking, reducing the amount of alcohol you drink, and reducing the amount of salt in your diet. Your doctor may also have recommended that you take regular exercise, such as walking or swimming. It is important to follow your doctor's advice.
Do not take Olmesartan/Hydrochlorothiazide MABO
If you think any of these apply to you, or if you are not sure, do not take the tablets. Talk to your doctor and follow their advice.
Warnings and precautions
Tell your doctor before you start taking Olmesartan/Hydrochlorothiazide MABO.
Before taking the tablets, tell your doctorif you are taking any of the following medicines used to treat high blood pressure:
Your doctor may want to check your kidney function, blood pressure, and blood electrolyte levels (e.g. potassium) at regular intervals.
See also the information under the heading “Do not take Olmesartan/Hydrochlorothiazide MABO”.
Before taking the tablets, tell your doctorif you have any of the following health problems:
Tell your doctor if you have any of the following conditions:
Tell your doctor if you have severe, persistent diarrhoea that causes significant weight loss. Your doctor will assess your symptoms and decide how to proceed with your treatment for high blood pressure.
Your doctor may want to see you more often and perform some tests if you have any of these problems.
Olmesartan/Hydrochlorothiazide MABO may cause an increase in blood fat and uric acid levels (which can cause gout - painful swelling of the joints). Your doctor will probably want to perform a blood test from time to time to check for these possible changes.
A change in blood electrolyte levels may occur. Your doctor will probably want to perform a blood test from time to time to check for this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling of weakness, slowness, tiredness, sleepiness or restlessness, nausea, vomiting, decreased need to urinate, rapid heartbeat. Tell your doctor if you notice any of these symptoms.
As with any other medicine that lowers blood pressure, excessive lowering of blood pressure in patients with impaired blood flow to the heart or brain may cause a heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.
If you are going to have parathyroid function tests, you must stop taking Olmesartan/Hydrochlorothiazide MABO before these tests are performed.
Athletes are informed that this medicine contains a component that may result in a positive doping test.
Tell your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will normally advise you to stop taking Olmesartan/Hydrochlorothiazide MABO before you become pregnant or as soon as you know you are pregnant, and will advise you to take a different medicine instead of Olmesartan/Hydrochlorothiazide MABO. It is not recommended to take Olmesartan/Hydrochlorothiazide MABO during pregnancy, and it must not be taken after the third month of pregnancy, as it may cause serious harm to your baby if taken after this time.
Tell your doctor if you experience abdominal pain, nausea, vomiting, or diarrhoea after taking Olmesartan/Hydrochlorothiazide MABO. Your doctor will decide whether to continue treatment.
Children and adolescents
Olmesartan/Hydrochlorothiazide MABO is not recommended for children and adolescents under 18 years of age.
Using Olmesartan/Hydrochlorothiazide MABO with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines:
Your doctor may need to change your dose and/or take other precautions:
If you are taking an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also the information under the headings “Do not take Olmesartan/Hydrochlorothiazide MABO” and “Warnings and precautions”).
Taking Olmesartan/Hydrochlorothiazide MABO with food and drink
Olmesartan/Hydrochlorothiazide MABO can be taken with or without food.
Be careful when drinking alcohol while taking Olmesartan/Hydrochlorothiazide MABO, as some people may feel faint or dizzy. If this happens, do not drink any alcohol, including wine, beer, or alcoholic drinks.
Black patients
As with other similar medicines, the blood pressure-lowering effect of Olmesartan/Hydrochlorothiazide MABO is somewhat less in black patients.
Pregnancy and breastfeeding
Pregnancy
Tell your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will normally advise you to stop taking Olmesartan/Hydrochlorothiazide MABO before you become pregnant or as soon as you know you are pregnant, and will advise you to take a different medicine instead of Olmesartan/Hydrochlorothiazide MABO. It is not recommended to take Olmesartan/Hydrochlorothiazide MABO during pregnancy, and it must not be taken after the third month of pregnancy, as it may cause serious harm to your baby if taken after this time.
Breastfeeding
Tell your doctor if you are breastfeeding or plan to breastfeed. It is not recommended to take Olmesartan/Hydrochlorothiazide MABO while breastfeeding, and your doctor may choose a different treatment for you if you want to breastfeed.
If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medicine.
Use in athletes
Athletes are informed that this medicine contains a component (hydrochlorothiazide) that may result in a positive doping test.
Driving and using machines
You may feel drowsy or dizzy while being treated for high blood pressure. If this happens, do not drive or use machines until the symptoms have disappeared. Consult your doctor.
Olmesartan/Hydrochlorothiazide MABO contains lactose
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
Take this medicine exactly as your doctor has told you. If you are not sure, consult your doctor or pharmacist.
The recommended dose is one Olmesartan/Hydrochlorothiazide MABO 40 mg/12.5 mg tablet per day. If your blood pressure is not controlled sufficiently, your doctor may change the dose to one Olmesartan/Hydrochlorothiazide MABO 40 mg/25 mg tablet per day.
Take the tablets with water. If possible, take your dose at the same time each day, e.g. at breakfast time. It is important that you continue to take Olmesartan/Hydrochlorothiazide MABO until your doctor tells you to stop.
If you take more Olmesartan/Hydrochlorothiazide MABO than you should
If you take more tablets than you should or if a child accidentally takes some, contact your doctor or go to the nearest hospital emergency department immediately and take the medicine pack with you.
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or call the Toxicology Information Service (tel. 91 562 04 20) stating the medicine and the amount taken.
If you forget to take Olmesartan/Hydrochlorothiazide MABO
If you forget to take a daily dose, take the normal dose the next day. Do not take a double dose to make up for forgotten doses.
If you stop taking Olmesartan/Hydrochlorothiazide MABO
It is important to continue taking Olmesartan/Hydrochlorothiazide MABO unless your doctor tells you to stop.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
However, the following adverse effects can be serious:
Olmesartan/Hydrochlorothiazide MABO may cause a pronounced drop in blood pressure in susceptible patients or as a result of an allergic reaction. Infrequently, fainting or dizziness may occur. If this happens to you, stop taking Olmesartan/Hydrochlorothiazide MABO, consult your doctor immediately, and remain lying down in a horizontal position.
Olmesartan/Hydrochlorothiazide MABO is a combination of two active ingredients. The following information first describes the adverse effects reported so far with the Olmesartan/Hydrochlorothiazide combination (in addition to those already mentioned) and, secondly, the known adverse effects of the two active ingredients separately.
These are other known adverse effects reported so far with Olmesartan/Hydrochlorothiazide:
If these effects occur, they are often mild and it is not necessary to interrupt treatment.
Frequent Adverse Effects (may affect up to 1 in 10 people):
Dizziness, weakness, headache, fatigue, chest pain, swelling of ankles, feet, legs, hands, or arms.
Infrequent Adverse Effects (may affect up to 1 in 100 people):
Fast and intense heartbeat (palpitations), rash, eczema, vertigo, cough, indigestion, abdominal pain, nausea, vomiting, diarrhea, muscle cramps, and muscle pain, joint pain, arm and leg pain, back pain, erection problems in men, blood in urine.
Also, some changes in blood test results have been observed infrequently, including:
Increased levels of fat in the blood, increased urea or uric acid in the blood, increased creatinine, increased or decreased potassium levels in the blood, increased calcium levels in the blood, increased blood sugar, increased liver function test values. Your doctor will monitor you with a blood test and tell you if you need to take any action.
Rare Adverse Effects (may affect up to 1 in 1,000 people):
Feeling of discomfort, altered consciousness, skin swelling (hives), acute kidney failure.
Also, some changes in blood test results have been observed rarely, including:
Increased blood urea nitrogen, decreased hemoglobin and hematocrit values. Your doctor will monitor you with a blood test and tell you if you need to take any action.
Intestinal angioedema: swelling in the intestine that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Additional Adverse Effects Reported with the Use of Olmesartan Medoxomil or Hydrochlorothiazide Alone, but Not with Olmesartan/Hydrochlorothiazide MABO or at a Higher Frequency:
Olmesartan Medoxomil:
Frequent Adverse Effects (may affect up to 1 in 10 people):
Bronchitis, cough, nasal congestion or secretion, sore throat, abdominal pain, indigestion, diarrhea, nausea, gastroenteritis, joint or bone pain, back pain, blood in urine, urinary tract infection, flu-like symptoms, pain.
Also, some changes in blood test results have been observed frequently, including:
Increased levels of fat in the blood, increased urea or uric acid in the blood, increased liver or muscle function test values.
Infrequent Adverse Effects (may affect up to 1 in 100 people):
Rapid allergic reactions that can affect the whole body and cause breathing problems, as well as a rapid drop in blood pressure that can lead to fainting (anaphylactic reactions), facial inflammation, angina (chest pain or discomfort known as angina pectoris), feeling of discomfort, allergic skin rash, itching, exanthema (skin rash), skin swelling (hives).
Also, some changes in blood test results have been observed infrequently, including:
Reduction in the number of a type of blood cells called platelets (thrombocytopenia).
Rare Adverse Effects (may affect up to 1 in 1,000 people):
Renal function impairment, lack of energy.
Also, some changes in blood test results have been observed rarely, including:
Increased potassium levels in the blood.
Hydrochlorothiazide:
Very Frequent Adverse Effects (may affect more than 1 in 10 people):
Changes in blood tests, including increased fat in the blood and uric acid levels.
Frequent Adverse Effects (may affect up to 1 in 10 people):
Feeling of confusion, abdominal pain, stomach discomfort, feeling of swelling, diarrhea, nausea, vomiting, constipation, glucose excretion in urine.
Also, some changes in blood test results have been observed, including:
Increased creatinine, urea, calcium, and blood sugar levels, decreased chloride, potassium, magnesium, and sodium levels in the blood. Increased serum amylase (hyperamylasemia).
Infrequent Adverse Effects (may affect up to 1 in 100 people):
Decreased or lost appetite, severe breathing difficulties, anaphylactic skin reactions (hypersensitivity reactions), worsening of pre-existing myopia, erythema, skin reactions due to light sensitivity, itching, purple spots or patches on the skin due to small hemorrhages (purpura), skin swelling (hives).
Rare Adverse Effects (may affect up to 1 in 1,000 people):
Inflammation and pain of the salivary glands, decreased white blood cell count, decreased platelet count in the blood, anemia, bone marrow depression, restlessness, depression, sleep problems, feeling of loss of interest (apathy), tingling and numbness, seizures, yellowish perception of objects when looking at them, blurred vision, dry eyes, irregular heartbeat, inflammation of blood vessels, blood clots (thrombosis or embolism), lung inflammation, fluid accumulation in the lungs, pancreatitis, jaundice, infection in the gallbladder, symptoms of lupus erythematosus such as skin rash, joint pain, and cold hands and fingers, allergic skin reactions, skin peeling and blisters, non-infectious kidney inflammation (interstitial nephritis), fever, muscle weakness (which sometimes causes movement disorders).
Very Rare Adverse Effects (may affect up to 1 in 10,000 people):
Electrolyte imbalance that can cause an abnormally reduced level of chloride in the blood (hypochloremic alkalosis), intestinal obstruction (paralytic ileus).
Acute respiratory distress (signs include severe respiratory distress, fever, weakness, and confusion).
Unknown Frequency:
Decreased vision or eye pain due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma), skin and lip cancer (non-melanoma skin cancer).
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
No special storage conditions are required.
Do not use this medicine after the expiration date shown on the packaging and blister pack (after "EXP.:"). The expiration date is the last day of the month indicated.
Medicines should not be disposed of through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Olmesartan/Hydrochlorothiazide MABO
The active ingredients are olmesartan medoxomil and hydrochlorothiazide. Each film-coated tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
The other components (excipients) are: lactose monohydrate, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, microcrystalline cellulose, magnesium stearate, titanium dioxide (E 171), macrogol, triacetin, hypromellose, yellow iron oxide (E 172), and red iron oxide (E 172).
Product Appearance and Package Contents:
Olmesartan/Hydrochlorothiazide MABO 40 mg/25 mg is presented in the form of film-coated tablets, pink, oval, 15 mm x 7 mm, with the inscription OH 42 on one face.
Olmesartan/Hydrochlorothiazide MABO film-coated tablets are presented in aluminum blisters, in packages of 28 tablets.
Marketing Authorization Holder:
MABO-FARMA, S.A.
Calle Vía de los Poblados 3,
Edificio 6, 28033, Madrid,
Spain.
Manufacturer:
Actavis Ltd.,
BLB 016 Bulebel Industrial Estate,
Zejtun ZTN 3000,
Malta.
Date of the Last Revision of this Prospectus: February 2025
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS)
http://www.aemps.gob.es/
The average price of OLMESARTAN/HYDROCHLOROTHIAZIDE MABO 40 mg/25 mg FILM-COATED TABLETS in October, 2025 is around 20.18 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OLMESARTAN/HYDROCHLOROTHIAZIDE MABO 40 mg/25 mg FILM-COATED TABLETS – subject to medical assessment and local rules.